Drugdocs | Vyvanse®

Drug updated on 9/4/2024

Dosage Form	Capsule (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg); Chewable tablet (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg)
Drug Class	Central nervous system stimulants
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

Indicated for the treatment of moderate to severe binge eating disorder (BED) in adults.

Vyvanse (lisdexamfetamine dimesylate) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older, as well as for the treatment of moderate to severe binge eating disorder (BED) in adults.
This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
Lisdexamfetamine (LDX) is effective in treating Binge-Eating Disorder (BED), consistently reducing BED symptoms and body weight in patients.
In adults with Attention-Deficit Hyperactivity Disorder (ADHD), LDX demonstrated the highest effect size in reducing ADHD symptoms (SMD = -0.89) compared to mixed amphetamine salts (SMD = -0.64) and methylphenidate (SMD = -0.50), indicating superior efficacy among psychostimulants.
No significant differences in serious adverse events were found between ADHD pharmacotherapies (including LDX) and placebo, although a higher proportion of participants withdrew due to adverse events in the pharmacotherapy group.
There were no specific safety outcomes or adverse effects detailed for LDX in the treatment of Binge-Eating Disorder (BED).
Few randomized controlled trials (RCTs) reported on long-term adverse events.
There is no population types or subgroups information available in the reviewed studies.

Document Title	Year	Source
Vyvanse (lisdexamfetamine dimesylate) Prescribing Information.	2023	Takeda Pharmaceuticals America, Inc., Lexington

Document Title	Year	Source
Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.	2021	European Neuropsychopharmacology
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.	2020	PLoS One
Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis.	2019	Annals of Pharmacotherapy

Document Title	Year	Source
Clinical practice guideline for the pharmacological and psychological treatment of adult patients with attention deficit hyperactivity disorder and a comorbid diagnosis of substance use disorder.	2023	Adicciones
The American Psychiatric Association practice guideline for the treatment of patients with eating disorders.	2022	American Psychiatric Association
Treatment strategies for ADHD: An evidence-based guide to select optimal treatment	2019	Molecular Psychiatry
Attention deficit hyperactivity disorder: Diagnosis and management. NICE guideline [NG87]	2019	NICE
Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: A critical look.	2019	BMJ Evidence-based Medicine